CD274 and head and neck squamous cell carcinoma: As of today, only the PD-L1 combined positive score (CPS) has been identified as a tool to select patients who could benefit from the use of pembrolizumab, alone or with chemotherapy, in platinum-sensitive HNSCC patients.